[Experimental models for the pharmacologic study of anti-arrhythmia drugs].
In order to assess the value and therapeutic safety of an antiarrhythmic drug, it must be submitted to multiple tests, which reproduce as faithfully as possible the conditions observed in human pathology. The main experimental approaches are presented here: screening and control tests. For each test, the authors emphasize the various experimental factors limiting their interpretation and allowing the extrapolation to men.
D000157:Aconitine / Q000494:pharmacology; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D001073:Aprindine / Q000494:pharmacology; D003331:Coronary Vessels / Q000502:physiology; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects; D007545:Isoproterenol / Q000494:pharmacology; D008026:Ligation; D009203:Myocardial Infarction / Q000209:etiology / Q000503:physiopathology; D010042:Ouabain / Q000494:pharmacology / Q000633:toxicity; D051381:Rats; D014693:Ventricular Fibrillation / Q000139:chemically induced / Q000503:physiopathology
D000889:Anti-Arrhythmia Agents; D010042:Ouabain; D001073:Aprindine; D007545:Isoproterenol; D000157:Aconitine
Modèles expérimentaux pour l'étude pharmacologique des anti-arythmiques.